Statera Biopharma Cash Per Share vs. Cash And Equivalents
STABDelisted Stock | USD 0.04 0.0003 0.82% |
For Statera Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Statera Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Statera Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Statera Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Statera Biopharma over time as well as its relative position and ranking within its peers.
Statera |
Statera Biopharma Cash And Equivalents vs. Cash Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Statera Biopharma's current stock value. Our valuation model uses many indicators to compare Statera Biopharma value to that of its competitors to determine the firm's financial worth. Statera Biopharma is currently regarded as top stock in cash per share category among its peers. It also is currently regarded as top stock in cash and equivalents category among its peers creating about 50,610,000 of Cash And Equivalents per Cash Per Share. Comparative valuation analysis is a catch-all model that can be used if you cannot value Statera Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Statera Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Statera Cash And Equivalents vs. Cash Per Share
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Statera Biopharma |
| = | 0.01 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Statera Biopharma |
| = | 506.1 K |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Statera Cash And Equivalents Comparison
Statera Biopharma is currently under evaluation in cash and equivalents category among its peers.
Statera Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Statera Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Statera Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Statera Biopharma's change in net profit over the period of time. It can combine multiple indicators of Statera Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropeniaanemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the bodys immune system and restore homeostasis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people.
Statera Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Statera Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Statera Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Statera Biopharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Statera Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
All Next | Launch Module |
Use Investing Themes to Complement your Statera Biopharma position
In addition to having Statera Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Banks - Regional Thematic Idea Now
Banks - Regional
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Banks - Regional theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banks - Regional Theme or any other thematic opportunities.
View All Next | Launch |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
CEOs Directory Screen CEOs from public companies around the world | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |